Coherus Biosciences Inc

NASDAQ:CHRS   3:59:52 PM EDT
11.48
-0.56 (-4.65%)
Products

Coherus And Junshi Biosciences Expand Immuno-Oncology Collaboration

Published: 01/10/2022 12:45 GMT
Coherus Biosciences Inc (CHRS) - Coherus and Junshi Biosciences Expand Immuno-oncology Collaboration to Include Tigit-targeted Antibody.
Coherus Biosciences Inc - Coherus and Junshi Biosciences Plan to Evaluate Toripalimab + Js006 Combination in Clinical Trials in Multiple Tumor Types.
Coherus Biosciences Inc - Will Pay Junshi Biosciences $35 Million Upfront, Up to $255 Million in Development Regulatory and Sales Milestones.
Coherus Biosciences - Initiated Process to Exercise Option to License Js006, Junshi Biosciences' Tigit-targeted Antibody, in United States, Canada.